Bartova, Lucie http://orcid.org/0000-0002-1769-8025
Lanzenberger, Rupert http://orcid.org/0000-0003-4641-9539
Rujescu, Dan http://orcid.org/0000-0002-1432-313X
Kasper, Siegfried http://orcid.org/0000-0001-8278-191X
Article History
Received: 10 August 2022
Revised: 11 January 2023
Accepted: 21 April 2023
First Online: 16 June 2023
Competing interests
: Within the last 3 years, LB has received travel grants and consultant/speaker honoraria from Alpine Market Research, Angelini, Biogen, Diagnosia, Dialectica, Janssen, Lundbeck, Market Access Transformation, Medizin Medien Austria, Novartis, Schwabe and Universimed. RL received travel grants and/or conference speaker honoraria from Bruker BioSpin within the last three years and investigator-initiated research funding from Siemens Healthcare regarding clinical research using PET/MR. He is a shareholder of the start-up company BM Health GmbH since 2019. Within the last three years, DR has received grant/research support from Janssen and Lundbeck; he has served as a consultant or on advisory boards for Janssen and Rovi and he has served on speakers bureaus of Janssen and Pharmagenetix. Within the last three years, SK has received grant/research support from Lundbeck; he has served as a consultant or on advisory boards for Angelini, Biogen, Esai, Janssen, IQVIA, Lundbeck, Mylan, Recordati, Sage and Schwabe; and he has served on speakers bureaus for Aspen Farmaceutica S.A., Angelini, Biogen, Janssen, Lundbeck, Neuraxpharma, Recordati, Sage, Sanofi, Schwabe, Servier and Sun Pharma.